<DOC>
	<DOCNO>NCT00415909</DOCNO>
	<brief_summary>Objectives : - To determine response rate duration response combination TALL-104 cell imatinib mesylate ( IM ) therapy patient chronic myelogenous leukemia chronic phase , achieve , lose , adequate response IM . - To determine toxicity combination TALL-104 cell IM therapy patient population .</brief_summary>
	<brief_title>TALL-104 Gleevec Chronic Myelogenous Leukemia Patients</brief_title>
	<detailed_description>Imatinib mesylate design block enzyme believe responsible start type leukemia patient . TALL-104 cell cell immune system obtain patient leukemia process laboratory try make able kill leukemia cell . If find eligible take part study , patient continue receive imatinib mesylate mouth schedule dose patient receive enter study . Patient receive TALL-104 cell needle vein 1 hour Days 1-4 , Days 7 , 10 , 14 , 17 , 21 cycle . The cycle last 28 day . Blood ( 1 tablespoon ) drawn every week first 4 week , every 2-4 week 2 month , every 4-6 week 6 month , every 3-6 month routine test check effect organ . Patient follow-up visit 1 month , 3 month , 6 month , least annually 2 year , least every 5 year rest life . Blood ( 1 teaspoon ) drawn check status disease . An additional 1 tablespoon also collect stored analyzed case unexpected side effect occur receive therapy . If patient experience certain side effect , blood may need drawn test perform base side effect experience . Up 20 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Patients CML chronic phase fail achieve lose adequate response IM . For purpose trial define lack cytogenetic response 6 month therapy lack major cytogenetic response 12 month therapy IM . Patients lose major complete cytogenetic response also eligible . Patients show sustained increase breakpoint cluster region gene ( BCR ) Abelson gene ( ABL ) /ABL [ BCRABL/ABL ] ratio &gt; /= 1log confirm least two consecutive Polymerase Chain Reaction ( PCR ) analyse ( least one month apart ) also eligible . 2 . *continued : Patients stable molecular response define 2 consecutive PCRpositive result ( 1/2 log improvement ) also eligible . Patients must take stable dose IM least 3 month study enrollment , recover toxicity relate IM , grade 01 . 3 . Patients complete partial hematological remission , include white blood count ( WBC ) &lt; /=20 x 10 ( 9 ) /L , platelet &lt; /= 600 x 10 ( 9 ) /L . 4 . Eastern Cooperative Oncology Group ( ECOG ) scale performance status 2 less . 5 . Age great 18 year age since disease extremely rare young age group . 6 . Adequate liver ( total bilirubin le 2 time aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) less 2 time upper limit normal ) , renal function ( creatinine less 2 time upper limit normal ) . 7 . Signed informed consent form . 8 . Negative pregnancy test woman childbearing age . 9 . Negative hepatitis B C screen blood test . 1 . Serious intercurrent medical illness active infection require parenteral antibiotic would interfere ability patient carry treatment program . 2 . Female patient pregnant breastfeeding . 3 . Patients take steroid , anticipate receive steroid trial therapy . 4 . Prior bone marrow transplant . 5 . Known positivity human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Gleevec</keyword>
	<keyword>TALL-104</keyword>
</DOC>